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Abstract 
Background: Sweet syndrome is a rare skin condition characterised by fever, neutrophilia, and tender erythematous 
skin lesions and has been reported to occur in association with anti-neutrophil cytoplasmic antibodies (ANCA) as well 
as complicate treatment with azathioprine therapy. Azathioprine, a relatively safe immunosuppressive, is frequently 
used to maintain disease remission in the treatment of ANCA-associated vasculitis. The occurrence of Sweet syn-
drome in a patient with ANCA-positive vasculitis and following treatment with azathioprine prompted us to present 
this clinical case and share this unusually rare occurrence. In doing so, we also wish to discuss current understanding 
of the disease and plausible associations.
Case presentation: Herein, we discuss the case of a 54-year old white male, who presented with features of ANCA 
vasculitis with haemoptysis, arthralgia, abnormal kidney function with active urine sediment and a positive p-ANCA 
titre. Standard immunosuppressive treatment with corticosteroids and intravenous rituximab resulted in disease 
remission. Due to significant steroid side effects, his steroid treatment was gradually tapered and switched to azathio-
prine over a 6-month period. Two weeks following initiation of azathioprine, he developed a painful maculo-papular 
erythematous skin rash and fever. A skin biopsy confirmed classical features consistent with Sweet syndrome. With-
drawal of azathioprine and treatment with oral corticosteroids and colchicine therapy resulted in complete resolution 
of the rash, although he continued to have high titres of MPO positive ANCA.
Conclusion: Sweet syndrome is a rare adverse reaction to azathioprine but has also been reported to occur in asso-
ciation with ANCA vasculitis. The temporal association with azathioprine in our case and the relatively rapid resolu-
tion of the skin vasculitis upon its withdrawal suggested a primarily drug-induced reaction rather than an associated 
feature of ANCA vasculitis.
© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Anti-neutrophil cytoplasmic antibody-associated vascu-
litis (ANCA-V) is a group of diseases characterised by 
inflammation and necrosis of small and medium sized-
blood vessels [1]. Azathioprine (AZA) is commonly 
used in the maintenance phase of this potentially life 
threatening disease in order to maintain remission after 
induction therapy [2]. Sweet syndrome, an acute febrile 
neutrophilic dermatosis, is a rare hypersensitivity reac-
tion that has been reported to occur following exposure 
to azathioprine and AZA induced Sweet syndrome was 
first described in 1995 [3]. To-date, a total of 18 cases 
have been reported after that first description [4]. In 
the majority of these cases, exposure to AZA treatment 
occurred in the setting of inflammatory bowel disease. 
Sweet syndrome has also been reported in association 
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with ANCA-V as highlighted in a recent French multi-
centre study [5]. To our knowledge, there are only two 
published case reports of AZA-induced Sweet syn-
drome in the literature where the underlying condition 
was ANCA-V [6, 7]. Causality is a difficult construct to 
prove in the circumstances of single isolated clinical 
cases. However, clearly defining the temporal sequence 
of events between the exposure and a specific outcome is 
suggestive of a strong association, especially if the condi-
tion disappears when the offending culprit is removed.
Case report
A 53-year old white male was referred to University Hos-
pital Limerick with a macular rash on extensor aspects 
of upper limb and torso, bilateral loin pain, arthralgia, 
fatigue, active urinary sediment and acute kidney injury in 
August 2015. The current presentation was preceded by 
two previous episodes of illness in which he had reported 
similar symptoms along with haemoptysis in April and 
July 2014. Past medical history revealed the presence of a 
peripapilary melanoma of the left eye treated with radi-
otherapy in 2010 and a basal cell carcinoma of the mid-
back excised in 2000. The patient denied tobacco use 
and drank occasionally and denied any family history off 
kidney disease. He worked on a farm and was married 
with two children. On presentation his blood pressure 
was 124/70 mmHg, weight 91 kg, and there was evidence 
of macular rash on his back but no lower limb oedema. 
Urine evaluation demonstrated activity with 3+ protein 
and 3+ blood, and his serum creatinine was elevated 
at 128  μmol/L compared to a baseline of 116  μmol/L 
recorded in April 2014. Serology was positive for P-ANCA 
with a titre of 160 and he had an anti-MPO titre of over 
200  units/mL; apart from this ANA was positive with a 
titre of 1600 with negative Anti-dsDNA, Anti-Sm, Anti-
Sm/RNP and Anti-SSB/RO/LA; Serology for HIV 1 + 2 
Ag/Ab and Hepatitis BsAg & Hepatitis C antibody were 
negative; complement levels were within normal range C3 
of 0.82 g/L and C4 of 0.24 g/L. ESR was 30 mm/h and Hs-
CRP was 48 mg/L; rest of his routine bloods were unre-
markable (White cell count 5.8 × 109/L, haemoglobin 
13.5  g/dL, neutrophils 4.00 × 109/L, platelet 210 × 109/L, 
sodium 141  mmol/L, potassium 4.2  mmol/L, total pro-
tein 69 g/L, albumin 39 g/L, serum calcium 2.31 mmol/L, 
serum phosphate 1.09  mmol/L, bilirubin 7.3  µmol/L, 
alkaline phosphatase 81  IU/L, gamma-glutamyl trans-
ferase 25  IU/L, alanine-aminotransferase 39  IU/L, pro-
thrombin time 12.0  s, activated partial thromboplastin 
time 32.0 s). Chest X-ray was normal. A recent ultrasound 
of his kidneys demonstrated normal size and shape with 
normal cortex. A native kidney biopsy revealed evidence 
of moderate arteriosclerosis with 30–35% fibrosis, areas 
of thrombotic microangiopathy but without evidence of 
fibrinoid necrosis or epithelial crescents. Immunofluo-
rescence was negative and electron microscopy revealed 
thin glomerular basement membranes with mean meas-
urements less than 250 nM and many measurements less 
than 200  nM, consistent with thin basement membrane 
disease (TBMD).
Based on the presence of an AKI with active urine 
sediment, associated skin rash, and positive serology 
with high titres of P-ANCA and anti-MPO along with 
an antecedent history of haemoptysis, we diagnosed an 
ANCA-associated vasculitis likely microscopic poly-
angiitis (MPA) based on the European Medicines Agency 
Algorithm, although the kidney biopsy sample failed 
to demonstrate classical features of renal vasculitis [8]. 
Treatment was initiated with corticosteroids and intra-
venous rituximab infusions (at day 0 and day 18) with 
prophylaxis for pneumocystis (co-trimoxazole), osteo-
porosis (oral Vitamin D3 and bisphosphonates), and 
gastritis (proton pump inhibitor). Four weeks later his 
urine sediment normalised with no detectable blood or 
protein; his CRP fell to < 5  mg/L and his ANCA titres 
fell to 40 but his anti-MPO level remained remarkably 
high 198 IU/mL. Two months later, he developed severe 
depression attributed to steroids requiring taper and the 
initiation of anti-psychotic therapy.
Six months following initial presentation, his vascu-
litis remained clinically quiescent and the patient was 
commenced on azathioprine (AZA) as a steroid spar-
ing agent for maintenance immunosuppression. Two 
weeks after AZA commencement, the patient presented 
to the emergency department with acute painful dis-
seminated morbilliform rash along with fever and myal-
gia. On examination temp was 39.7 °C and a widespread 
indurated erythematous papular rash was noted (Fig. 1a, 
b). An extensive viral and immunologic work up was 
negative including virology for herpes zoster, and sim-
plex. Considering his history of immunosuppression he 
was empirically started on acyclovir. Full blood count 
revealed neutrophilic leucocytosis with neutrophil count 
of 12.2 × 109/L, Hs-CRP 259 and ESR 59, and a stable 
serum creatinine concentration of 115  μmol/L. A full 
septic work up was negative including negative serology 
for HIV, hepatitis A, B, C, and CMV. A skin biopsy was 
diagnostic of Sweet’s syndrome, in which the affected 
lesions revealed extensive neutrophilic infiltrate in the 
dermis but without evidence of leukocytoclastic vasculi-
tis, herpes, zoster, or erythema multiform. Azathioprine 
was stopped and the patient was treated with oral predni-
solone (30 mg once daily followed by a steroid taper) and 
colchicine (500 mcg twice daily) [9]. Within 4 weeks, the 
rash had completely resolved (Fig. 1c, d) and his inflam-
matory markers normalised. As the onset of symptoms 
were temporally related to initiation of AZA, a diagnosis 
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of drug-induced Sweet syndrome. His steroid dose was 
tapered gradually to zero and treatment with colchicine 
was continued. As of August 2017, his vasculitis remains 
quiescent and there has been no recurrence of Sweet syn-
drome, however his ANCA titres remain elevated with 
anti-MPO levels 170 RU/mL.
Fig. 1 a Abrupt onset of disseminated painful skin lesions. b Target lesions visible with areas of confluence. c After 2 weeks of steroid therapy and 
AZA withdrawal. d After 4 weeks of steroids and addition of colchicine
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Discussion
We highlight the positive association of MPA with 
the presence of Sweet’s syndrome in this case report, 
which is characterised by an intense neutrophilic infil-
trate of the dermis. The combination of neutrophilic 
dermatoses and ANCA-V has only been described 
in a few case reports. A recent retrospective multi-
centre study, by the French Internal Medicine Soci-
ety (SNFMI) and the French Vasculitis Study Group 
(FVSG), found that Sweets syndrome occurred in three 
of four patients with MPA suggesting a strong associa-
tion [5]. It is noteworthy from this review that Sweets 
syndrome pre-dated the onset of ANCA disease in 
some patients, and either occurred contemporane-
ously or followed the onset of ANCA disease in oth-
ers, suggesting possible external triggers. Our patient 
with MPA developed classic features of Sweets syn-
drome within 2  weeks of exposure to AZA therapy. 
The close temporal association between the exposure 
to AZA and the development of the skin manifesta-
tions, the subsequent resolution after withdrawal of 
AZA, and treatment with steroids and colchicine sug-
gests a likely causal relationship. Given the strength 
of this association, we speculated that the occurrence 
of Sweets syndrome was primarily a result of AZA 
rather than the underlying ANCA vasculitis. AZA is 
known to cause many adverse reactions including a 
well described entity known as azathioprine hypersen-
sitivity syndrome (AHS), which commonly presents as 
an acute febrile neutrophilic dermatosis. It is difficult 
to distinguish between AHS and AZA induced Sweet 
syndrome as they have a very similar presentation 
[4]. While our case shares many features with AHS, 
the morphology together with the distribution of the 
lesions predominantly on the head, neck, and trunk 
and the biopsy findings of dense neutrophilic infiltrate 
with marked papillary oedema (Fig. 2) lead us to inter-
pret it as AZA induced Sweets syndrome rather than 
Sweet’s like or azathioprine hypersensitivity syndrome. 
Given the similarities between the two entities and the 
fatal outcomes of AHS, re-challenge of the drug should 
be avoided. From literature review, we identified two 
previous cases of AZA-induced Sweet syndrome where 
ANCA vasculitis was the underlying condition [6, 7]. 
In each case, patients were positive for MPO-ANCA 
with evidence of renal involvement and treated with 
cyclophosphamide. Moreover, the skin rash appeared 
with commencement of AZA therapy, and in both 
cases complete resolution occurred on stopping 
the drug along with treatment with corticosteroids. 
Despite these strong temporal associations, there are 
some case reports where Sweets syndrome was diag-
nosed at the first presentation of ANCA vasculitis and 
without exposure to medication suggesting a strong 
linkage with ANCA disease [5].
Sweet syndrome is classified into three types: (1) clas-
sical Sweet syndrome, (2) malignancy associated Sweet 
syndrome and (3) drug induced Sweet syndrome [10]. 
The criteria for drug-induced Sweet syndrome include 
the following: (1) abrupt onset of painful erythematous 
plaques, (2) histopathologic evidence of dense neutro-
philic infiltrate without evidence of leukocytoclastic 
vasculitis, (3) temperature higher than 38  °C, (4) tem-
poral relationship between drug exposure and clinical 
presentation, and (5) temporal resolution of lesions after 
drug withdrawal [11]. In our case, the skin rash appeared 
2  weeks after commencement of AZA therapy, and 
resolved after cessation of therapy and a short course of 
steroids. This temporality of events suggests that AZA 
was the culprit rather than the ANCA vasculitis, which 
preceded the skin syndrome by at least 6 months.
Conclusion
We report a case of Sweets syndrome following exposure 
to AZA in a patient with pre-existing ANCA vasculitis. 
Although rare, it is prudent to consider AZA-induced 
Sweet syndrome in patients presenting with fever and 
rash within weeks of initiating AZA therapy after exclud-
ing infection, malignancy and acute flare of vasculitis. 
Moreover, the role of ANCA antibodies cannot be com-
pletely ignored, and prudence would suggest that patients 
presenting with Sweets syndrome should be comprehen-
sively investigated for underlying ANCA vasculitis.
Abbreviations
ANCA: anti-neutrophil cytoplasmic antibodies; ANCA-V: anti-neutrophil 
cytoplasmic antibody-associated vasculitis; AZA: azathioprine; TBMD: thin 
basement membrane disease.
Fig. 2 Histopathology of skin biopsy: skin with normal epidermis. 
There is a diffuse neutrophilic dermal infiltrate with papillary dermal 
oedema and no evidence of acute vasculitis
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